Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )

8.750 +0.010 (+0.11%)
Streaming Delayed Price Updated: 12:21 PM EDT, May 19, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,480
Open 8.730
Bid (Size) 8.740 (1)
Ask (Size) 8.790 (2)
Prev. Close 8.740
Today's Range 8.565 - 8.950
52wk Range 6.510 - 33.41
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Amylyx Pharmaceuticals Announces Publication of Data Showing Randomization to AMX0035 Prolonged Tracheostomy/Ventilation-free Survival and Reduced Occurrence of First Hospitalization
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-51.58%
-51.58%
1 Month
-17.22%
-17.22%
3 Month
-59.90%
-59.90%
6 Month
-51.58%
-51.58%
1 Year
-51.58%
-51.58%

More News

Read More
Amylyx Pharmaceuticals Announces Publication of New CENTAUR Trial Analyses Further Demonstrating Significant Survival Benefit with AMX0035 in People with ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Expert Ratings For Amylyx Pharmaceuticals
Via Benzinga
FDA Panel Votes Down For Amylyx's ALS Drug, Further Fading Its Hope For Regulatory Success
Via Benzinga
92 Biggest Movers From Friday
Via Benzinga
Amylyx Pharma Stock Hinges On This FDA Action — Here's What To Know
Via Investor's Business Daily
Amylyx Shares Plummet On Skeptical FDA Adcomm Docs On ALS Drug
Via Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Via Benzinga
Amylyx Pharmaceuticals Announces Oral Presentation of Safety and Tolerability Data on AMX0035 from Clinical Trials at 2022 American Academy of Neurology Annual Meeting
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Reata Stock Enjoys A Two-Day Climb — Why It Could Still Be Facing Everest
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For April 1, 2022
Via Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
Via Benzinga
Amylyx Pharmaceuticals Reports Full Year 2021 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting on AMX0035 for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
Via Benzinga
Amylyx Pharmaceuticals Stock Trading Halted Today
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
50 Biggest Movers From Yesterday
Via Benzinga
Mid-Day Market Update: Crude Oil Dips 8%; Plantronics Shares Spike Higher
Via Benzinga
35 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Amylyx Pharmaceuticals Stock Crashes As FDA Doubts Its ALS Treatment
Via Investor's Business Daily
Amylyx Pharmaceuticals Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on AMX0035
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Mid-Morning Market Update: Markets Mixed; SAIC Profit Tops Views
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.